BRPI0821116A2 - Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer - Google Patents

Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer

Info

Publication number: BRPI0821116A2
Authority: BR; Brazil
Prior art keywords: cancer; compound; treating; pharmaceutical composition; composition containing
Prior art date: 2007-12-20

Application number

BRPI0821116-7A

Other languages

English (en)

Inventor

Alberto Rodríguez Vicente

Carmen Murcia Pérez

Francisco Sánchez Sancho

María Del Carmen Cuevas Marchante

María Garranzo García-Ibarrola

Cristina Mateo Urbano

Isabel Digón Juárez

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-20

Filing date

2008-12-19

Publication date

2015-08-11

2008-12-19 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2015-08-11 Publication of BRPI0821116A2 publication Critical patent/BRPI0821116A2/pt

2020-02-18 Publication of BRPI0821116B1 publication Critical patent/BRPI0821116B1/pt

2021-05-25 Publication of BRPI0821116B8 publication Critical patent/BRPI0821116B8/pt

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title abstract 2
241000124008 Mammalia Species 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Compounds Of Unknown Constitution (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)

BRPI0821116A 2007-12-20 2008-12-19 composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo BRPI0821116B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07123882		2007-12-20
EP07123882.8		2007-12-20
PCT/EP2008/068049 WO2009080761A1 (en)	2007-12-20	2008-12-19	Antitumoral compounds

Publications (3)

Publication Number	Publication Date
BRPI0821116A2 true BRPI0821116A2 (pt)	2015-08-11
BRPI0821116B1 BRPI0821116B1 (pt)	2020-02-18
BRPI0821116B8 BRPI0821116B8 (pt)	2021-05-25

Family

ID=40580474

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0821116A BRPI0821116B8 (pt)	2007-12-20	2008-12-19	composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
BRPI0821114A BRPI0821114B8 (pt)	2007-12-20	2008-12-19	Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BRPI0821114A BRPI0821114B8 (pt)	2007-12-20	2008-12-19	Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto

Country Status (26)

Country	Link
US (4)	US8710264B2 (pt)
EP (3)	EP2231633B1 (pt)
JP (3)	JP5529038B2 (pt)
KR (3)	KR101639772B1 (pt)
CN (4)	CN102190643B (pt)
AT (1)	ATE549313T1 (pt)
AU (2)	AU2008341671B2 (pt)
BR (2)	BRPI0821116B8 (pt)
CA (2)	CA2715203C (pt)
CY (1)	CY1117245T1 (pt)
DK (2)	DK2231590T3 (pt)
ES (3)	ES2384420T3 (pt)
HR (2)	HRP20140015T1 (pt)
IL (3)	IL206396A (pt)
MX (2)	MX2010006795A (pt)
MY (3)	MY148651A (pt)
NZ (3)	NZ597526A (pt)
PL (2)	PL2231590T3 (pt)
PT (2)	PT2231590E (pt)
RS (2)	RS53140B (pt)
RU (3)	RU2493147C2 (pt)
SG (2)	SG170778A1 (pt)
SI (2)	SI2231590T1 (pt)
UA (3)	UA106967C2 (pt)
WO (2)	WO2009080769A1 (pt)
ZA (3)	ZA201004017B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20140015T1 (hr)	2007-12-20	2014-02-14	Pharma Mar, S.A.	Antitumorski spojevi
WO2013103155A1 (en) *	2012-01-05	2013-07-11	Kao Corporation	Agent for reduction of sensory irritation
MA38588B1 (fr)	2013-04-16	2018-04-30	Idorsia Pharmaceuticals Ltd	Dérivés bi-aromatiques antibactériens
GB201309807D0 (en) *	2013-05-31	2013-07-17	Pharma Mar Sau	Antibody drug conjugates
CN108467378A (zh) *	2017-02-23	2018-08-31	复旦大学	一种二氢吡喃酮类化合物及其制备方法和用途
LT3615544T (lt)	2017-04-27	2023-05-10	Pharma Mar S.A.	Priešnavikiniai junginiai
TWI824043B (zh)	2018-10-25	2023-12-01	西班牙商瑪製藥股份有限公司	藥物抗體共軛物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5142056A (en) *	1989-05-23	1992-08-25	Abbott Laboratories	Retroviral protease inhibiting compounds
US4855086A (en)	1982-10-15	1989-08-08	Burroughs Wellcome Co.	Novel pesticides, preparation and use
JPS61109717A (ja)	1984-11-02	1986-05-28	Teruhiko Beppu	抗腫瘍剤
JPH06504547A (ja) *	1990-12-28	1994-05-26	ジョージア・テック・リサーチ・コーポレーション	ペプチドケトアミド、ケト酸およびケトエステル
JPH0539283A (ja)	1991-01-31	1993-02-19	Suntory Ltd	新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en)	1992-11-13	1995-04-28	Upjohn Co	Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en)	1994-09-29	1996-06-04	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5681847A (en) *	1995-12-05	1997-10-28	Harbor Branch Oceanographic Institution, Inc.	Methods of using discodermolide compounds
US5834506A (en)	1996-11-01	1998-11-10	Warner-Lambert Company	Dihydropyrones with improved antiviral activity
US5840974A (en) *	1996-12-04	1998-11-24	Britisch Biotech Pharmaceuticals, Ltd.	Metalloproteinase inhibitors
US6380400B1 (en)	1998-09-11	2002-04-30	Victor Fedij	Methods of making dihydropyrone HIV protease inhibitors
US6528510B1 (en)	1998-09-11	2003-03-04	Warner-Lambert Company	HIV protease inhibitors
AU2000241948A1 (en) *	2000-04-04	2001-10-15	Novartis Ag	Method for treating cells resistant to antineoplastic agents
MXPA04008577A (es) *	2002-03-04	2005-07-13	Aton Pharma Inc	Metodos para inducir diferenciacion terminal.
AU2004263287B2 (en) *	2003-07-25	2009-02-12	Novartis Ag	Substituted lactams and their use as anti-cancer agents
RU2006142690A (ru) *	2004-06-03	2008-06-10	Козан Байосайенсиз Инкорпорейтед (Us)	Соединения лептомицина
US7446196B2 (en)	2004-06-03	2008-11-04	Kosan Biosciences, Incorporated	Leptomycin compounds
WO2007014423A1 (en) *	2005-08-02	2007-02-08	Medvet Science Pty, Ltd.	Exercise apparatus
EP2404912A3 (en)	2006-06-16	2012-07-25	Pharma Mar S.A.	Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
HRP20140015T1 (hr)	2007-12-20	2014-02-14	Pharma Mar, S.A.	Antitumorski spojevi

2008
- 2008-12-19 HR HRP20140015AT patent/HRP20140015T1/hr unknown
- 2008-12-19 CA CA2715203A patent/CA2715203C/en active Active
- 2008-12-19 CA CA2710087A patent/CA2710087C/en active Active
- 2008-12-19 UA UAA201009034A patent/UA106967C2/uk unknown
- 2008-12-19 DK DK08865009.8T patent/DK2231590T3/da active
- 2008-12-19 US US12/746,966 patent/US8710264B2/en not_active Expired - Fee Related
- 2008-12-19 PT PT08865009T patent/PT2231590E/pt unknown
- 2008-12-19 BR BRPI0821116A patent/BRPI0821116B8/pt not_active IP Right Cessation
- 2008-12-19 DK DK08864895.1T patent/DK2231633T3/da active
- 2008-12-19 SG SG201102163-1A patent/SG170778A1/en unknown
- 2008-12-19 SG SG201102164-9A patent/SG170779A1/en unknown
- 2008-12-19 RU RU2010130180/04A patent/RU2493147C2/ru active
- 2008-12-19 EP EP08864895.1A patent/EP2231633B1/en active Active
- 2008-12-19 CN CN201110073931.0A patent/CN102190643B/zh not_active Expired - Fee Related
- 2008-12-19 MY MYPI2010002590A patent/MY148651A/en unknown
- 2008-12-19 MY MYPI2010002591A patent/MY155342A/en unknown
- 2008-12-19 CN CN2008801218410A patent/CN101903337B/zh not_active Expired - Fee Related
- 2008-12-19 WO PCT/EP2008/068065 patent/WO2009080769A1/en not_active Ceased
- 2008-12-19 KR KR1020157016575A patent/KR101639772B1/ko not_active Expired - Fee Related
- 2008-12-19 JP JP2010538765A patent/JP5529038B2/ja not_active Expired - Fee Related
- 2008-12-19 MX MX2010006795A patent/MX2010006795A/es active IP Right Grant
- 2008-12-19 PL PL08865009T patent/PL2231590T3/pl unknown
- 2008-12-19 NZ NZ597526A patent/NZ597526A/en not_active IP Right Cessation
- 2008-12-19 JP JP2010538769A patent/JP5727228B2/ja not_active Expired - Fee Related
- 2008-12-19 WO PCT/EP2008/068049 patent/WO2009080761A1/en not_active Ceased
- 2008-12-19 KR KR1020107015965A patent/KR101541436B1/ko not_active Expired - Fee Related
- 2008-12-19 KR KR1020107015968A patent/KR101579553B1/ko not_active Expired - Fee Related
- 2008-12-19 ES ES08865009T patent/ES2384420T3/es active Active
- 2008-12-19 UA UAA201009035A patent/UA104281C2/ru unknown
- 2008-12-19 UA UAA201406894A patent/UA119963C2/uk unknown
- 2008-12-19 MX MX2010006796A patent/MX2010006796A/es active IP Right Grant
- 2008-12-19 AU AU2008341671A patent/AU2008341671B2/en not_active Ceased
- 2008-12-19 RU RU2013112003/04A patent/RU2528393C9/ru active
- 2008-12-19 AU AU2008341670A patent/AU2008341670B2/en not_active Ceased
- 2008-12-19 CN CN200880121840.6A patent/CN101903367B/zh not_active Expired - Fee Related
- 2008-12-19 EP EP13154647.5A patent/EP2597091B1/en active Active
- 2008-12-19 ES ES08864895.1T patent/ES2442140T3/es active Active
- 2008-12-19 RU RU2010130253/04A patent/RU2489429C2/ru active
- 2008-12-19 SI SI200830644T patent/SI2231590T1/sl unknown
- 2008-12-19 NZ NZ586013A patent/NZ586013A/en not_active IP Right Cessation
- 2008-12-19 RS RS20140007A patent/RS53140B/sr unknown
- 2008-12-19 NZ NZ586012A patent/NZ586012A/en not_active IP Right Cessation
- 2008-12-19 MY MYPI2014002392A patent/MY164533A/en unknown
- 2008-12-19 PT PT88648951T patent/PT2231633E/pt unknown
- 2008-12-19 PL PL08864895T patent/PL2231633T3/pl unknown
- 2008-12-19 AT AT08865009T patent/ATE549313T1/de active
- 2008-12-19 CN CN2011100568656A patent/CN102174058A/zh active Pending
- 2008-12-19 EP EP08865009A patent/EP2231590B9/en active Active
- 2008-12-19 US US12/746,974 patent/US9187445B2/en active Active
- 2008-12-19 RS RS20120242A patent/RS52343B/sr unknown
- 2008-12-19 HR HRP20120464AT patent/HRP20120464T1/hr unknown
- 2008-12-19 ES ES13154647.5T patent/ES2578606T3/es active Active
- 2008-12-19 BR BRPI0821114A patent/BRPI0821114B8/pt not_active IP Right Cessation
- 2008-12-19 SI SI200831122T patent/SI2231633T1/sl unknown
2010
- 2010-06-04 ZA ZA2010/04017A patent/ZA201004017B/en unknown
- 2010-06-04 ZA ZA2010/04018A patent/ZA201004018B/en unknown
- 2010-06-15 IL IL206396A patent/IL206396A/en active IP Right Grant
- 2010-06-15 IL IL206397A patent/IL206397A/en active IP Right Grant
2011
- 2011-08-31 ZA ZA2011/06371A patent/ZA201106371B/en unknown
2013
- 2013-11-24 IL IL229594A patent/IL229594A/en active IP Right Grant
2014
- 2014-01-27 CY CY20141100069T patent/CY1117245T1/el unknown
- 2014-04-10 JP JP2014080887A patent/JP5860088B2/ja not_active Expired - Fee Related
2015
- 2015-08-12 US US14/824,699 patent/US9827257B2/en not_active Expired - Fee Related
- 2015-08-12 US US14/824,690 patent/US9750759B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NZ586012A (en)	2011-11-25
US20100280108A1 (en)	2010-11-04
BRPI0821114B1 (pt)	2021-09-08
JP2014133752A (ja)	2014-07-24
EP2231590B1 (en)	2012-03-14
HK1147990A1 (en)	2011-08-26
MY155342A (en)	2015-10-15
BRPI0821114B8 (pt)	2021-11-09
RU2493147C2 (ru)	2013-09-20
IL206397A (en)	2014-01-30
JP5529038B2 (ja)	2014-06-25
JP5860088B2 (ja)	2016-02-16
CN101903367A (zh)	2010-12-01
IL206396A (en)	2014-05-28
CN102174058A (zh)	2011-09-07
US9187445B2 (en)	2015-11-17
HK1180678A1 (en)	2013-10-25
IL206396A0 (en)	2010-12-30
US20120041063A2 (en)	2012-02-16
EP2231633B1 (en)	2013-10-30
JP5727228B2 (ja)	2015-06-03
IL206397A0 (en)	2010-12-30
MX2010006796A (es)	2010-10-26
UA106967C2 (uk)	2014-11-10
MY164533A (en)	2017-12-29
RU2013112003A (ru)	2014-08-20
DK2231590T3 (da)	2012-07-09
US20150344454A1 (en)	2015-12-03
ES2442140T3 (es)	2014-02-25
JP2011506575A (ja)	2011-03-03
CN102190643A (zh)	2011-09-21
PL2231633T3 (pl)	2014-03-31
SI2231590T1 (sl)	2012-10-30
RU2528393C9 (ru)	2015-01-10
EP2231633A1 (en)	2010-09-29
EP2597091A1 (en)	2013-05-29
IL229594A (en)	2016-02-29
AU2008341670B2 (en)	2012-04-19
PT2231590E (pt)	2012-06-25
UA104281C2 (ru)	2014-01-27
RU2528393C1 (ru)	2014-09-20
ZA201106371B (en)	2013-05-29
CN101903367B (zh)	2015-08-05
BRPI0821116B1 (pt)	2020-02-18
JP2011506578A (ja)	2011-03-03
CN101903337A (zh)	2010-12-01
HK1147998A1 (en)	2011-08-26
RS52343B (sr)	2012-12-31
SI2231633T1 (sl)	2014-02-28
ES2384420T3 (es)	2012-07-04
AU2008341671B2 (en)	2012-07-26
KR20150076265A (ko)	2015-07-06
SG170779A1 (en)	2011-05-30
HRP20120464T1 (hr)	2012-07-31
ZA201004018B (en)	2011-12-28
US9827257B2 (en)	2017-11-28
CA2710087A1 (en)	2009-07-02
MX2010006795A (es)	2010-10-26
AU2008341670A1 (en)	2009-07-02
CN101903337B (zh)	2013-12-18
KR101541436B1 (ko)	2015-08-03
IL229594A0 (en)	2014-01-30
US8710264B2 (en)	2014-04-29
RS53140B (sr)	2014-06-30
CN102190643B (zh)	2015-02-25
RU2010130180A (ru)	2012-01-27
KR101579553B1 (ko)	2015-12-22
RU2489429C2 (ru)	2013-08-10
WO2009080761A1 (en)	2009-07-02
BRPI0821116B8 (pt)	2021-05-25
SG170778A1 (en)	2011-05-30
CA2710087C (en)	2015-06-02
US20150342972A1 (en)	2015-12-03
KR101639772B1 (ko)	2016-07-15
MY148651A (en)	2013-05-15
UA119963C2 (uk)	2019-09-10
US9750759B2 (en)	2017-09-05
PT2231633E (pt)	2014-01-20
WO2009080769A1 (en)	2009-07-02
EP2231590B9 (en)	2012-08-15
DK2231633T3 (da)	2014-01-20
HRP20140015T1 (hr)	2014-02-14
CA2715203C (en)	2015-09-08
BRPI0821114A2 (pt)	2015-06-16
EP2597091B1 (en)	2016-04-20
AU2008341671A1 (en)	2009-07-02
ATE549313T1 (de)	2012-03-15
KR20100125226A (ko)	2010-11-30
ES2578606T3 (es)	2016-07-28
EP2231590A1 (en)	2010-09-29
PL2231590T3 (pl)	2012-09-28
US20110034549A1 (en)	2011-02-10
ZA201004017B (en)	2011-12-28
RU2010130253A (ru)	2012-01-27
NZ586013A (en)	2012-02-24
KR20100100979A (ko)	2010-09-15
NZ597526A (en)	2012-06-29
CY1117245T1 (el)	2017-04-05
CA2715203A1 (en)	2009-07-02

Legal Events

Date	Code	Title	Description
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-04-16	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-12-24	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-02-18	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-10-15	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2025-02-04	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2806 DE 15-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0717845A2 (pt)	2015-06-16	Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
CO6270257A2 (es)	2011-04-20	Derivados de piridazinona
ECSP067062A (es)	2007-01-26	Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
ECSP077401A (es)	2007-05-30	Medicamentos que contienen compuestos de carbonilo y su uso
CL2007003520A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
ECSP088598A (es)	2008-08-29	Derivados de piridazinona
CL2010000188A1 (es)	2011-04-01	Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
DK1961418T3 (da)	2012-07-23	Anvendelse af isothiocyanatforbindelser til behandling af prostatasygdomme og hudcancer
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CY1111437T1 (el)	2015-08-05	Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
UY29633A1 (es)	2007-01-31	Derivados de oxindol
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
BRPI0606112A2 (pt)	2009-06-02	3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
BRPI0811816A2 (pt)	2014-12-30	"forma de dosagem de picoplatina estabilizada, método para preparar uma forma de dosagem de picoplatina estabilizada, composições, kit, pluralidade de kits, método para tratamento de câncer e uso de uma quantidade eficaz da forma de dosagem"
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
PA8720801A1 (es)	2008-11-19	Nuevas combinaciones terapeuticas para el tratamiento de la depresion
GT200900201A (es)	2011-06-23	Formulaciones para el tratamiento del cáncer.
CL2008001782A1 (es)	2008-11-03	Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
DOP2006000268A (es)	2007-07-31	Agentes antibacterianos
BRPI0821114A2 (pt)	2015-06-16	Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer
ECSP066986A (es)	2006-12-29	Beta-carbolinas utiles para tratar enfermedades inflamatorias
ECSP099389A (es)	2009-07-31	Nuevas formas cristalinas
CL2007003847A1 (es)	2008-04-18	Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.
AR069639A1 (es)	2010-02-10	Composicion de nanoparticulas con superficie modificada
BRPI0519006A2 (pt)	2008-12-23	uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos